Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful diligently but unsuccessfully to develop an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past several shares of mine. My first CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire job interview which I came away with a bad impression of the business.

Irony of irony, my poor opinion of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of the technology and associated intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) and also the very first new drug program endorsement ($five million), and also royalty payments of five % of net sales after commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple therapies and many indications, it has this single treatment in addition to a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Could all this be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very beginning of the interest of mine in this particular organization. Judging with the multiples of thousands of various comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a classic battleground, or perhaps some may say cult stock. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *